Business Wire

ELLIOTT-ADVISORS-(UK)

19.7.2018 09:32:05 CEST | Business Wire | Press release

Share
Elliott Advisors (UK) Statement on thyssenkrupp AG

Funds advised by Elliott Advisors (UK) Limited (“Elliott”) are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”).

Elliott notes recent press coverage referencing the contents of a private letter Elliott sent to the thyssenkrupp Supervisory Board yesterday morning. In order to avoid any misunderstandings or misrepresentations of its substance, Elliott is hereby making the full text of the letter public.

***

The Members of the Supervisory Board

thyssenkrupp AG

thyssenkrupp Allee 1

45143 Essen


18 July 2018

Ladies and Gentlemen,

We note the resignation of Professor Dr. Ulrich Lehner as chairman of the Supervisory Board of thyssenkrupp AG.

When we met with Professor Lehner in Essen on 27th June he and we assured each other of our desire to develop a constructive working relationship. Professor Lehner’s comments in the interview he gave to Die Zeit on 12th July suggest that he did not give those assurances in good faith.

In the course of the interview with Die Zeit Professor Lehner gave his account of the current situation at thyssenkrupp and specifically singled out three shareholders: Krupp-Stiftung, Cevian and Elliott. Against this background, he denounced the behavior of certain ‘activist investors’ as ‘psycho-terror’ and accused them of ‘placing lies in public’, making ‘unjustified requests for resignations’, causing executives to seek ‘psychiatric counselling’ or even going as far as ‘harassing families and neighbours’, concluding that such shareholders are ‘not a benefit’ to the company. Any reasonable reader of this interview would have concluded that he was accusing Elliott of engaging in such behavior. To be clear, any such accusation is categorically untrue and is defamatory. As Professor Lehner could not have had any evidence for such accusations, we assume that he made them maliciously or, at least recklessly.

Our engagement with Professor Lehner and, before him, Dr Hiesinger in respect of thyssenkrupp cannot be described as anything other than the reasonable actions of a responsible, concerned and engaged investor. We have not at any stage, and contrary to Professor Lehner’s comments, demanded a dismantling (‘Zerschlagung’) of thyssenkrupp. Nevertheless, the company should continue to consider any structural evolution, such as the Steel JV, where such changes are determined to be in the interests of all stakeholders. You will be aware that, prior to our meeting with Professor Lehner, we had written to Dr Hiesinger on 24th May indicating our support for the Steel JV while at the same time pointing to analytical indicators that suggested better terms should be achievable in the negotiation. For that reason, we expected the Management Board to have negotiated a better transaction for the benefit of all stakeholders and the final outcome is therefore, from our point of view, very disappointing. The negotiated transaction relinquishes control over one of thyssenkrupp’s key legacy assets, and contributes it to a JV at a value considerably below that which could have been achieved. This view is shared by other investors and stakeholders, and arguably the board, given that the terms of the JV were ultimately amended, albeit insufficiently in our opinion.

We do not know if Professor Lehner’s resignation was required or requested by the Supervisory Board in response to his Die Zeit interview. We would expect that in circumstances where its chairman has made statements that untruthfully disparage shareholders the Supervisory Board would wish to take steps to remedy that situation. We therefore consider that it would be appropriate for the company and the Supervisory Board to distance itself from Professor Lehner’s defamatory remarks by publicly stating that the company does not support them and does not view them as truthful. To the extent the company is in a position to do so, it should take steps to ensure that Professor Lehner publicly withdraws these falsehoods and does not repeat them.

Notwithstanding these recent events, we hope that Professor Lehner’s resignation will now allow Elliott to establish the constructive working relationship with the new chairman and the Supervisory Board that we had hoped to build with him.

In that spirit, we look forward to the appointment of a new Chairman of the Supervisory Board in the short term and we welcome the appointment of Guido Kerkhoff as interim CEO, in that it provides some stability to the group prior to the appointment of a new Chief Executive. However, this interim period must be kept short so that thyssenkrupp may quickly be set on a path to prosperity and growth. Shareholders expect an unbiased search for a new external CEO, driven by what is best for the company and all of its stakeholders, including shareholders.


Yours faithfully,


Elliott Advisors (UK) Limited

About Elliott

Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

Contact:

Media Contacts
London
Elliott Advisors (UK) Limited
Sarah Rajani CFA, +44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Germany
Charles Barker Corporate Communications
Thomas Katzensteiner / Tobias Eberle, +49 69 79 40 90 25 / 24
Thomas.katzensteiner@charlesbarker.de / tobias.eberle@charlesbarker.de

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release

Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release

Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye